Tech Company Financing Transactions
Fibronostics Funding Round
On 8/25/2020, Fibronostics landed $8 million in Series A funding from AT Capital Group, elev8.vc and private investors.
Transaction Overview
Company Name
Announced On
8/25/2020
Transaction Type
Venture Equity
Amount
$8,000,000
Round
Series A
Investors
AT Capital Group (Lead Investor)
elev8.vc (Lead Investor)
Proceeds Purpose
The financing will accelerate the commercialization of LIVERFASt in the U.S. and help the company expand its SaaS platform with new products targeting other disease states, including COVID-19, kidney and lung diseases.
Company Information
Company Status
Private & Independent
Industry
Healthcare IT
Mailing Address
3452 Lake Lynda Dr. Bldg 100 151
Orlando, FL 32817
USA
Orlando, FL 32817
USA
Phone
Website
Email Address
Overview
Founded in 2017, Fibronostics comprises of a team of physicians, data scientists and life science experts driven to improve healthcare with technology. Here in Fibronostics, we believe in advancing non-invasive diagnostic and prognostic methods with to aid healthcare professionals and provide patients with better clinical outcome.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Roni Amiel
Chief Financial Officer
Thomas Fratacci
Chief Medical Officer
Ronald Quiambao
Chief Technical Officer
Abhishek Aravind
VP - Bus. Development
Lloyd Isberto
VP - Bus. Development
Missy Martin-Kemp
VP - Operations
Aida Jailani
Browse more venture capital transactions:
Prev: 8/25/2020: Dataiku venture capital transaction
Next: 8/25/2020: One Drop venture capital transaction
Share this article
Where The Data Comes From
We do our best to document funding rounds that are announced publicly. VC transactions reported here are derived from company press releases and news coverage. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs